The Lupus Foundation of America said Tuesday that a discussion of the positive results of a recent Phase II clinical study of Anifrolumab, a potential treatment for systemic lupus, is available on its website.
Anifrolumab is an antibody that fights against the Type I interferon (IFN) receptor that inhibits the activity of all Type I IFNs, from which lupus often originates.
In the study, Anifrolumab produced positive results in 34.4 percent of the patients who were administered 300-milligram doses and in 28.8 percent of the patients who received 1,000-milligram doses.
Dr. Richard Alan Furie, chief of the Division of Rheumatology at North Shore-LIJ Health System, discusses the results in the podcast.
Data gleaned from the study was presented Monday during the American College of Rheumatology's annual scientific meeting in San Francisco.